WHAT’S NEW

PIPELINE

Research and Development

TECHNOLOGY

SMTPs, which represents a group of more than 60 compounds with related structures, are the core elements of our pipeline of new drug candidates at TMS. SMTPs exhibit remarkable activities including promotion of physiological thrombolysis, suppression of inflammation, and antioxidation.

TMS-007

An SMTP congener with prothrombolytic and anti-inflammatory/antioxidative activities: under clinical development for acute ischemic stroke treatment (positive phase 2a results with respect to both safety and efficacy)

TMS-008

An SMTP congener with anti-inflammatory/antioxidative activities: under nonclinical development for inflammatory complications such as acute kidney injury and cancer cachexia

TMS-010

under nonclinical development for spinal cord injury